Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:34 2024-06-21 EDT 		5-day change 1st Jan Change
14.48 HKD +3.58% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. -0.69% -51.57%
06-03 ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug MT
05-30 ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. Stock ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
-51.57% 694M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.19% 121B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.91% 114B
B+
BIONTECH SE Stock BioNTech SE
-19.80% 20.43B
B+
GENMAB A/S Stock Genmab A/S
-16.19% 16.55B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.45% 16.45B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.59B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+66.67% 15.19B
C+
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.13% 13.54B
C+
INSMED INCORPORATED Stock Insmed Incorporated
+119.39% 10.96B
C
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 1541 Stock
  4. Ratings ImmuneOnco Biopharmaceuticals (Shanghai) Inc.